Skip to main content
Kickstart your weight-loss journey now—with 6 months free!

Review of commercial weight management programs in the United States

By Weight Watchers
Last updated December 6, 2023
Review of commercial weight management programs in the United States

When commercial weight-loss programs were compared to control/education or behavioral counseling among overweight and obese adults based on weight-loss efficacy, adherence, and harms, Weight Watchers was ranked as one of the top programs in the 2015 Annals of Internal Medicine review.

The Johns Hopkins University researchers identified 141 commercial and proprietary weight-loss programs, and focused on the 32 that incorporated nutrition and behavioral counseling. Of these programs, only 11 had data published from randomized controlled trials (RCTs) or prospective studies that tested their effectiveness.

The review found that of the three companies leading the market share—Jenny Craig, Nutrisystem, and Weight Watchers—there were 14 published RCTs and eight of those included Weight Watchers. The review found that Weight Watchers consistently has greater weight losses than control/education participants and sustained it beyond 12 months, with low risk for adverse events. The authors concluded that: “ Clinicians might consider prioritizing referral only for those commercial programs that have a substantial body of evidence showing a consistent long-term effect.

How Weight Watchers compares to Jenny Craig, Nutrisystem, and other weight-loss programs

Program

Intensity

Support

Monthly
Cost

USPSTF
Criteria

RCTs

Return to the Science Center

This content is for general educational and informational purposes. The content is not medical advice, does not diagnose any medical condition and is not a substitute for professional medical advice, diagnosis or treatment from a healthcare provider. Talk to your healthcare provider about any medical concerns.

Trust: You need this newsletter.

The field of weight management is evolving–and fast. New research. New treatments. Lots of misinformation. Our clinical newsletter helps sort it all out.